A Phase 3 interventional study of Somatropin and Somatropin in Growth Hormone Therapy and Infant, Small for Gestational Age, sponsored by Pfizer. Terminated at 10 sites in Germany. Open to participants aged 6 Years to 10 Years. Per ClinicalTrials.gov, last updated 2012-02-29.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The planned study focuses on the effect of a one year Somatropin treatment (0.035 mg/kg/d or 0.067 mg/kg/d) in short children born SGA on neuromuscular function and cognitive performance.
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Somatropin for 12 months
Drug: Somatropin
In the first 6 months no intervention, afterwards Somatropin for 12 months
Drug: Somatropin
Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6
Peak jump power (PJP) was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during two-leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population.
Time frame: Baseline and Month 6
Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6
PJP was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during two-leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population.
Time frame: Baseline and Month 6
Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6
PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during two-leg jump. The SDS indicates how similar the participant was to the reference population.
Time frame: Baseline and Month 6
Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6
PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during two-leg jump. The SDS indicates how similar the participant was to the reference population.
Time frame: Baseline and Month 6
Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6
Vmax was measured by Leonardo Jumping Platform during two-leg jump.
Time frame: Baseline and Month 6
Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Per Protocol (PP) Population at Month 6
Vmax was measured by Leonardo Jumping Platform during two-leg jump.
Time frame: Baseline and Month 6
Change From Baseline in Intellectual Performance of Children Using Kaufmann-Assessment Battery for Children (K-ABC) Test Global Scales at Month 6
K-ABC was assessed in children between 2.5-12.5 years. Comprised of 16 subtests; 10 mental processing (intelligence) and 6 achievement subtests. Achievement subtests: expressive vocabulary, faces\&places, arithmetic, riddles, reading/decoding, reading/comprehension. Sixteen subtests were weighted accordingly to form 5 global scales: sequential processing, simultaneous processing, achievement, non-verbal and mental processing composite. Scores were rated as upper extreme \[greater than (\>) 131\], above average (116-130), average (85-115), below average (70-84), lower extreme \[less than (\<) 69\].
Time frame: Baseline and Month 6
Change From Baseline in Intellectual Performance of Children Using Kaufmann-Assessment Battery for Children (K-ABC) Test Global Scales at Months 12 and 18
K-ABC was assessed in children between 2.5-12.5 years. Comprised of 16 subtests; 10 mental processing (intelligence) and 6 achievement subtests. Achievement subtests: expressive vocabulary, faces\&places, arithmetic, riddles, reading/decoding, reading/comprehension. Sixteen subtests were weighted accordingly to form 5 global scales: sequential processing, simultaneous processing, achievement, non-verbal and mental processing composite. Scores were rated as upper extreme \[greater than (\>) 131\], above average (116-130), average (85-115), below average (70-84), lower extreme \[less than (\<) 69\].
Time frame: Baseline, Month 12 and Month 18
Change From Baseline in Intellectual Performance of Children Using Kinderversion Der Testbatterie Zur Aufmerksamkeitsprüfung für Kinder (KITAP) Test at Month 6
The KITAP is a computer aided standardized neuro-cognitive development test which allows examination of a wide range of attention and executive functions such as shift of attention (Distractibility); simple reaction time (Alertness); "Sustained Attention", change of reaction (Flexibility); "Divided Attention", controlled reaction disposition (Go/No go) and "Vigilance". It has been designed appropriately for children between the age of 6 to 10 years to allow optimal motivation during testing and to increase validity of results.
Time frame: Baseline and Month 6
Change From Baseline in Intellectual Performance of Children Using Kinderversion Der Testbatterie Zur Aufmerksamkeitsprüfung für Kinder (KITAP) Test at Months 12 and 18
The KITAP is a computer aided standardized neuro-cognitive development test which allows examination of a wide range of attention and executive functions such as shift of attention (Distractibility); simple reaction time (Alertness); "Sustained Attention", change of reaction (Flexibility); "Divided Attention", controlled reaction disposition (Go/No go) and "Vigilance". It has been designed appropriately for children between the age of 6 to 10 years to allow optimal motivation during testing and to increase validity of results.
Time frame: Baseline, Month 12 and Month 18
Change From Baseline in Intellectual Performance of Children Using Non-verbal Learning Test (NVLT) at Month 6
NVLT was assessed for visual memorization that was difficult to verbalize. Test recorded instability index, T-scores\[sum of differences of correct {C} - incorrect {IC} "Yes" answers(1);sum of C "Yes" answers(2);sum of IC "Yes" answers(3);sum of differences of C-IC "Yes" answers with high associative items{ 87%-95%}(4);sum of differences of C-IC "Yes" answers with low associative items{ 54%-64%}(5); difference between difference values for high and low associative items(6)\].Scores were rated as below average(\<40), average(40-60), above average(\>60) and working time ranging between 9-12 minutes.
Time frame: Baseline and Month 6
Change From Baseline in Intellectual Performance of Children Using Non-verbal Learning Test (NVLT) at Months 12 and 18
NVLT was assessed for visual memorization that was difficult to verbalize. Test recorded instability index, T-scores\[sum of differences of correct {C} - incorrect {IC} "Yes" answers(1);sum of C "Yes" answers(2);sum of IC "Yes" answers(3);sum of differences of C-IC "Yes" answers with high associative items{ 87%-95%}(4);sum of differences of C-IC "Yes" answers with low associative items{ 54%-64%}(5); difference between difference values for high and low associative items(6)\].Scores were rated as below average(\<40), average(40-60), above average(\>60) and working time ranging between 9-12 minutes.
Time frame: Baseline, Month 12 and Month 18
Change From Baseline in Intellectual Performance of Children Using Child Behavior Checklist 4-18 Years (CBCL 4-18) at Months 6, 12 and 18
CBCL was standardized for children ages 4 to 18 years and measured child internalizing and externalizing behaviors and total problems. The 4-18 years' checklist contains 140 questions and responses were recorded on a Likert scale: 0 = Not True, 1 = Somewhat or Sometimes True, 2 = Very True or Often True. The range of possible values was 0-280 (0=good to 280=worst).
Time frame: Baseline, Month 6, Month 12 and Month 18
Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; One-leg-jump) at Months 6, 12 and 18
PJP was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during one leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population.
Time frame: Baseline, Month 6 , Month 12 and Month 18
Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; One-leg-jump) at Months 6, 12 and 18
PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during one leg jump. The SDS indicates how similar the participant was to the reference population.
Time frame: Baseline, Month 6, Month 12 and Month 18
Change From Baseline in Maximum Jump Velocity (Vmax; One-leg-jump) at Months 6, 12 and 18
Vmax was measured by Leonardo Jumping Platform during one leg jump.
Time frame: Baseline, Month 6, Month 12 and Month 18
Change From Baseline in Five-chair Rising Test- Peak Jump Power (PJP) at Month 6
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJP is defined as the peak of the calculated power (force multiplied by velocity).
Time frame: Baseline and Month 6
Change From Baseline in Five-chair Rising Test-Peak Jump Power (PJP) at Months 12 and 18
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJP is defined as the peak of the calculated power (force multiplied by velocity).
Time frame: Baseline, Month 12 and Month 18
Change From Baseline in Five-chair Rising Test-Peak Jump Force (PJF) at Month 6
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest.
Time frame: Baseline and Month 6
Change From Baseline in Five-chair Rising Test-Peak Jump Force (PJF) at Months 12 and 18
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest.
Time frame: Baseline, Month 12 and Month 18
Change From Baseline in Five-chair Rising Test-Maximum Jump Velocity (Vmax) at Month 6
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). Vmax is defined as the maximum jump velocity.
Time frame: Baseline and Month 6
Change From Baseline in Five-chair Rising Test-Maximum Jump Velocity (Vmax) at Months 12 and 18
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). Vmax is defined as the maximum jump velocity.
Time frame: Baseline, Month 12 and Month 18
Change From Baseline in Five-chair Rising Test (Time to Perform the Tasks) at Month 6
Chair rising test is performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: 5 repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over chest (time to perform tasks, maximal PJP, maximal velocity and maximal PJF). Time to perform task includes: Average (avg) rise time which is avg time to perform 1 rise, avg time per test is the avg time to perform 1 test (rise and sitting down) and total time to perform 5 tests.
Time frame: Baseline and Month 6
Change From Baseline in Five-chair Rising Test (Time to Perform the Tasks) at Months 12 and 18
Chair rising test is performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: 5 repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over chest (time to perform tasks, maximal PJP, maximal velocity and maximal PJF). Time to perform task includes: Average (avg) rise time which is avg time to perform 1 rise, avg time per test is the avg time to perform 1 test (rise and sitting down) and total time to perform 5 tests.
Time frame: Baseline, Month 12 and Month 18
Change From Baseline in One-chair Rising Test-Peak Jump Power (PJP) at Months 6, 12 and 18
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising). PJP is defined as the peak of the calculated power (force multiplied by velocity).
Time frame: Baseline, Month 6 , Month 12 and Month 18
Change From Baseline in One-chair Rising Test-Peak Jump Force (PJF) at Months 6, 12 and 18
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest.
Time frame: Baseline, Month 6 , Month 12 and Month 18
Change From Baseline in One-chair Rising Test (Time to Perform the Tasks) at Months 6, 12 and 18
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising).
Time frame: Baseline, Month 6 , Month 12 and Month 18
Change From Baseline in Maximal Isometric Grip Force-Standard Deviation Score (MIGF-SDS) at Month 6
MIGF was assessed using standard adjustable Jamar dynamometer. MIGF (in Newtons) was calculated by multiplying the dynamometer reading (in kilograms) by a factor of 9.81. The SDS indicates how similar the participant was to the reference population.
Time frame: Baseline and Month 6
Change From Baseline in Maximal Isometric Grip Force-Standard Deviation Score (MIGF-SDS) at Months 12 and 18
MIGF was assessed using standard adjustable Jamar dynamometer. MIGF (in Newtons) was calculated by multiplying the dynamometer reading (in kilograms) by a factor of 9.81. The SDS indicates how similar the participant was to the reference population.
Time frame: Baseline, Month 12 and Month 18
Mean Upper Arm Circumference
Time frame: Baseline, Month 6, Month 12 and Month 18
Mean Thigh Circumference
Thigh measurements were taken as a mean of 3 consecutive measurements at upper thigh about an inch down from the crotch line.
Time frame: Baseline, Month 6, Month 12 and Month 18
Mean Calf Circumference
Calf measurements were taken as a mean of 3 consecutive measurements at largest part of calf muscle, usually about 4 inches down from below the knee.
Time frame: Baseline, Month 6, Month 12 and Month 18
Mean Height at Month 6
Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer.
Time frame: Month 6
Mean Height at Months 12 and 18
Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer.
Time frame: Month 12 and Month 18
Mean Growth Velocity at Month 6
Growth velocity measures the annual rate of increase in height.
Time frame: Month 6
Mean Growth Velocity at Months 12 and 18
Growth velocity measures the annual rate of increase in height.
Time frame: Month 12 and Month 18
Mean Height-Standard Deviation Score (SDS) at Month 6
Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population.
Time frame: Month 6
Mean Height-Standard Deviation Score (SDS) at Months 12 and 18
Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population.
Time frame: Month 12 and Month 18
Mean Growth Velocity-Standard Deviation Score (SDS) at Month 6
Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population.
Time frame: Month 6
Mean Growth Velocity-Standard Deviation Score (SDS) at Months 12 and 18
Time frame: Month 12 and Month 18
Change From Baseline in Height-Standard Deviation Score (SDS) at Month 6
Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population.
Time frame: Baseline and Month 6
Change From Baseline in Height-Standard Deviation Score (SDS) at Months 12 and 18
Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population.
Time frame: Baseline, Month 12 and Month 18
Change From Baseline in Growth Velocity-Standard Deviation Score (SDS) at Month 6
Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population.
Time frame: Baseline and Month 6
Change From Baseline in Growth Velocity-Standard Deviation Score (SDS) at Months 12 and 18
Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population.
Time frame: Baseline, Month 12 and Month 18
Sitting Height-Standard Deviation Score (SDS)
Sitting height was measured using a stadiometer with a specialized chair. The SDS indicates how similar the participant was to the reference population.
Time frame: Baseline, Month 6, Month 12 and Month 18
Body Mass Index-Standard Deviation Score (BMI-SDS)
The BMI was used to measure body fat based on height and weight. It was calculated by body weight (kg) divided by the height (m) squared. The SDS indicates how similar the participant was to the reference population.
Time frame: Baseline, Month 6, Month 12 and Month 18
Change From Baseline in Head Circumference at Months 6, 12 and 18
The maximum head circumference (usually horizontal just above the eyebrow ridges), was measured from just above the glabella area to the area near the top of the occipital bone (opisthocranion).
Time frame: Baseline, Month 6, Month 12 and Month 18
Change From Baseline in Head Circumference-Standard Deviation Score (SDS) at Months 6, 12 and 18
The maximum head circumference (usually horizontal just above the eyebrow ridges), was measured from just above the glabella area to the area near the top of the occipital bone (opisthocranion). The SDS indicates how similar the participant was to the reference population.
Time frame: Baseline, Month 6, Month 12 and Month 18
Change From Baseline in Skinfold Thickness-Standard Deviation Score (SDS) at Month 6
Triceps, supra-iliac and subscapular skinfolds were measured on the right side of the body to the nearest 0.1 mm with a Holtain skinfold caliper. The measurement was performed at the left side of the participant. Triceps skinfold thickness was measured halfway down the left upper arm, while the arm was hanging relaxed at the participant's side. Suprascapular skinfold was measured laterally just below the angle of the left scapula. Suprailiac skinfold was measured just above the iliac crest in the middle-axillary line. SDS indicates how similar the participant was to the reference population.
Time frame: Baseline and Month 6
Change From Baseline in Skinfold Thickness-Standard Deviation Score (SDS) at Months 12 and 18
Triceps, supra-iliac and subscapular skinfolds were measured on the right side of the body to the nearest 0.1 mm with a Holtain skinfold caliper. The measurement was performed at the left side of the participant. Triceps skinfold thickness was measured halfway down the left upper arm, while the arm was hanging relaxed at the participant's side. Suprascapular skinfold was measured laterally just below the angle of the left scapula. Suprailiac skinfold was measured just above the iliac crest in the middle-axillary line. SDS indicates how similar the participant was to the reference population.
Time frame: Baseline, Month 12 and Month 18
Change From Baseline in Bone Density Using Peripheral Quantitative Computed Tomography (pqCT) at 6 or 12 or 18 Months
Bone Mineral Density (BMD) was measured by pqCT. The Z-score measures the distance of the measured BMD value from the appropriate normal age matched population mean value in units of standard deviation of this population. More negative scores indicate less BMD compared to age matched population and more positive scores indicate higher BMD compared to age matched population.
Time frame: Baseline, Month 6, Month 12 and Month 18
Change From Baseline in Bone Structure Using Peripheral Quantitative Computed Tomography (pqCT) at 6 or 12 or 18 Months
Bone structure was measured by pqCT.Parameters included:total area,cortical area,marrow area,cortical thickness,cortical density of the radius,bone strength,cross-sectional muscle and fat area,total bone density,bone mineral count,trabecular BMD,bone cross-sectional area.Baseline and post-baseline SDS values transformed to age and sex specific z-score(\[Ln(test result/M)\]/S);Ln=natural logarithm;M=age-/height- and sex-specific mean value;S=age-/height- and sex-specific coefficient of variation).Positive values are above the average for participant's age and sex;negative values are below.
Time frame: Baseline, Month 6, Month 12 and Month 18
Change From Baseline in Bone Stability Using Peripheral Quantitative Computed Tomography (pqCT) at 6 or 12 or 18 Months
Bone stability was measured by pqCT. Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- (or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.
Time frame: Baseline, Month 6, Month 12 and Month 18
| Milestone | Somatropin | Control Arm |
|---|---|---|
| Started | 12 | 11 |
| Treated | 12 | 10 |
| Completed | 8 | 5 |
| Not completed | 4 | 6 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Does not meet inclusion criteria | 1 | 0 |
| Withdrew: Terminated by sponsor | 2 | 5 |
| Withdrew: Randomized but not treated | 0 | 1 |
Peak jump power (PJP) was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during two-leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population.
| Watt/kilogram (W/kg) | Somatropin | Control Arm |
|---|---|---|
| Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6 | -0.15 ± 1.01 | 0.28 ± 0.51 |
PJP was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during two-leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population.
| W/kg | Somatropin | Control Arm |
|---|---|---|
| Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6 | -1.02 ± 0.43 | 0.59 ± 0.27 |
PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during two-leg jump. The SDS indicates how similar the participant was to the reference population.
| Newtons | Somatropin | Control Arm |
|---|---|---|
| Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6 | -0.70 ± 0.62 | -0.55 ± 0.29 |
K-ABC was assessed in children between 2.5-12.5 years. Comprised of 16 subtests; 10 mental processing (intelligence) and 6 achievement subtests. Achievement subtests: expressive vocabulary, faces\&places, arithmetic, riddles, reading/decoding, reading/comprehension. Sixteen subtests were weighted accordingly to form 5 global scales: sequential processing, simultaneous processing, achievement, non-verbal and mental processing composite. Scores were rated as upper extreme \[greater than (\>) 131\], above average (116-130), average (85-115), below average (70-84), lower extreme \[less than (\<) 69\].
| Units on a scale | Somatropin | Control Arm |
|---|---|---|
| Baseline (Sequential Processing) | 25.7 ± 8.35 | 28.5 ± 8.33 |
| Change at Month 6 (Sequential Processing) | 2.6 ± 5.82 | -1.9 ± 4.15 |
| Baseline (Simultaneous Processing) | 45.7 ± 7.20 | 49.8 ± 12.74 |
| Change at Month 6 (Simultaneous Processing) | -0.1 ± 4.53 | 1.5 ± 4.30 |
| Baseline (Achievement) | 300.7 ± 66.83 | 341.8 ± 76.88 |
| Change at Month 6 (Achievement) | 32.1 ± 48.79 | 16.7 ± 27.52 |
| Baseline (Nonverbal) | 46.2 ± 8.65 | 49.8 ± 13.21 |
| Change at Month 6 (Nonverbal) | -1.4 ± 3.78 | 0.0 ± 5.35 |
| Baseline (Mental Processing Composite) | 70.0 ± 12.38 | 78.1 ± 19.95 |
| Change at Month 6 (Mental Processing Composite) | 1.4 ± 6.39 | -0.9 ± 7.28 |
K-ABC was assessed in children between 2.5-12.5 years. Comprised of 16 subtests; 10 mental processing (intelligence) and 6 achievement subtests. Achievement subtests: expressive vocabulary, faces\&places, arithmetic, riddles, reading/decoding, reading/comprehension. Sixteen subtests were weighted accordingly to form 5 global scales: sequential processing, simultaneous processing, achievement, non-verbal and mental processing composite. Scores were rated as upper extreme \[greater than (\>) 131\], above average (116-130), average (85-115), below average (70-84), lower extreme \[less than (\<) 69\].
No measurements were reported for this outcome.
The KITAP is a computer aided standardized neuro-cognitive development test which allows examination of a wide range of attention and executive functions such as shift of attention (Distractibility); simple reaction time (Alertness); "Sustained Attention", change of reaction (Flexibility); "Divided Attention", controlled reaction disposition (Go/No go) and "Vigilance". It has been designed appropriately for children between the age of 6 to 10 years to allow optimal motivation during testing and to increase validity of results.
| Seconds | Somatropin | Control Arm |
|---|---|---|
| Baseline (Distractibility) | 554.3 ± 201.08 | 514.5 ± 127.41 |
| Change at 6 Month (Distractibility) (n= 7, 10) | 5.6 ± 230.95 | -11.4 ± 139.52 |
| Baseline (Alertness) | 433.9 ± 140.74 | 384.6 ± 124.94 |
| Change at 6 Month (Alertness) (n= 8, 10) | -16.1 ± 80.85 | 4.0 ± 107.42 |
| Baseline (Flexibility) | 1350.0 ± 470.50 | 1313.0 ± 477.19 |
| Change at 6 Month (Flexibility) (n= 8, 10) | -192.0 ± 492.73 | -211.0 ± 589.41 |
| Baseline (Go/No Go) | 539.8 ± 106.73 | 514.9 ± 91.95 |
| Change at 6 Month (Go/No Go) (n= 8, 9) | 35.6 ± 113.38 | -50.2 ± 69.90 |
| Baseline (Vigilance) | 822.2 ± 200.65 | 693.4 ± 118.01 |
| Change at 6 Month (Vigilance) (n= 7, 10) | -146.0 ± 278.60 | -31.2 ± 107.62 |
The KITAP is a computer aided standardized neuro-cognitive development test which allows examination of a wide range of attention and executive functions such as shift of attention (Distractibility); simple reaction time (Alertness); "Sustained Attention", change of reaction (Flexibility); "Divided Attention", controlled reaction disposition (Go/No go) and "Vigilance". It has been designed appropriately for children between the age of 6 to 10 years to allow optimal motivation during testing and to increase validity of results.
No measurements were reported for this outcome.
NVLT was assessed for visual memorization that was difficult to verbalize. Test recorded instability index, T-scores\[sum of differences of correct {C} - incorrect {IC} "Yes" answers(1);sum of C "Yes" answers(2);sum of IC "Yes" answers(3);sum of differences of C-IC "Yes" answers with high associative items{ 87%-95%}(4);sum of differences of C-IC "Yes" answers with low associative items{ 54%-64%}(5); difference between difference values for high and low associative items(6)\].Scores were rated as below average(\<40), average(40-60), above average(\>60) and working time ranging between 9-12 minutes.
| Units on a scale | Somatropin | Control Arm |
|---|---|---|
| Baseline (Instability Index) | 0.3 ± 0.15 | 0.2 ± 0.21 |
| Change at Month 6 (Instability Index) | -0.1 ± 0.11 | -0.1 ± 0.20 |
| Baseline (Working Time) | 227.0 ± 44.27 | 218.3 ± 76.89 |
| Change at Month 6 (Working Time) | 10.6 ± 92.95 | -11.1 ± 34.86 |
| Baseline [T-scores (1)] | 39.9 ± 13.60 | 43.9 ± 16.53 |
| Change at Month 6 [T-scores (1)] | 4.4 ± 11.64 | 6.7 ± 12.12 |
| Baseline [T-scores (2)] | 41.6 ± 12.97 | 46.8 ± 14.40 |
| Change at Month 6 [T-scores (2)] | 5.0 ± 10.72 | -0.6 ± 5.50 |
| Baseline [T-scores (3)] | 45.9 ± 14.89 | 48.1 ± 18.20 |
| Change at Month 6 [T-scores (3)] | 1.5 ± 5.15 | 8.3 ± 12.24 |
| Baseline [T-scores (4)] | 39.3 ± 16.97 | 46.4 ± 16.03 |
| Change at Month 6 [T-scores (4)] | 5.6 ± 15.53 | 1.4 ± 11.75 |
| Baseline [T-scores (5)] | 43.3 ± 11.12 | 43.6 ± 15.13 |
| Change at Month 6 [T-scores (5)] | 2.6 ± 9.83 | 7.7 ± 12.59 |
| Baseline [T-scores (6)] | 44.9 ± 15.83 | 52.9 ± 19.96 |
| Change at Month 6 [T-scores (6)] | 0.9 ± 16.55 | -7.4 ± 14.88 |
| Baseline [Age-corrected T-scores (1)] | 33.4 ± 12.18 | 38.6 ± 13.43 |
| Change at Month 6 [Age-corrected T-scores (1)] | 6.0 ± 10.21 | 5.2 ± 11.26 |
| Baseline [Age-corrected T-scores (2)] | 51.3 ± 7.55 | 54.5 ± 8.10 |
| Change at Month 6 [Age-corrected T-scores (2)] | 3.1 ± 5.59 | -0.1 ± 3.38 |
| Baseline [Age-corrected T-scores (3)] | 40.0 ± 13.86 | 41.1 ± 16.38 |
| Change at Month 6 [Age-corrected T-scores (3)] | 0.6 ± 4.47 | 7.8 ± 12.13 |
| Baseline [Age-corrected T-scores (4)] | 37.4 ± 17.01 | 45.0 ± 15.21 |
| Change at Month 6 [Age-corrected T-scores (4)] | 6.3 ± 14.57 | 4.1 ± 10.63 |
| Baseline [Age-corrected T-scores (5)] | 35.0 ± 11.88 | 37.3 ± 13.48 |
| Change at Month 6 [Age-corrected T-scores (5)] | 3.3 ± 10.73 | 6.9 ± 12.57 |
| Baseline [Age-corrected T-scores (6)] | 50.0 ± 16.49 | 55.5 ± 16.64 |
| Change at Month 6 [Age-corrected T-scores (6)] | 1.5 ± 19.06 | -4.1 ± 13.77 |
NVLT was assessed for visual memorization that was difficult to verbalize. Test recorded instability index, T-scores\[sum of differences of correct {C} - incorrect {IC} "Yes" answers(1);sum of C "Yes" answers(2);sum of IC "Yes" answers(3);sum of differences of C-IC "Yes" answers with high associative items{ 87%-95%}(4);sum of differences of C-IC "Yes" answers with low associative items{ 54%-64%}(5); difference between difference values for high and low associative items(6)\].Scores were rated as below average(\<40), average(40-60), above average(\>60) and working time ranging between 9-12 minutes.
No measurements were reported for this outcome.
CBCL was standardized for children ages 4 to 18 years and measured child internalizing and externalizing behaviors and total problems. The 4-18 years' checklist contains 140 questions and responses were recorded on a Likert scale: 0 = Not True, 1 = Somewhat or Sometimes True, 2 = Very True or Often True. The range of possible values was 0-280 (0=good to 280=worst).
No measurements were reported for this outcome.
PJP was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during one leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population.
No measurements were reported for this outcome.
PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during one leg jump. The SDS indicates how similar the participant was to the reference population.
No measurements were reported for this outcome.
Vmax was measured by Leonardo Jumping Platform during one leg jump.
No measurements were reported for this outcome.
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJP is defined as the peak of the calculated power (force multiplied by velocity).
| kilowatt (kW) | Somatropin | Control Arm |
|---|---|---|
| Baseline | 0.1 ± 0.07 | 0.1 ± 0.05 |
| Change at Month 6 | 0.0 ± 0.07 | 0.0 ± 0.05 |
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJP is defined as the peak of the calculated power (force multiplied by velocity).
No measurements were reported for this outcome.
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest.
| kilonewton (kN) | Somatropin | Control Arm |
|---|---|---|
| Baseline | 0.4 ± 0.11 | 0.4 ± 0.19 |
| Change at Month 6 | -0.0 ± 0.23 | 0.0 ± 0.20 |
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest.
No measurements were reported for this outcome.
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). Vmax is defined as the maximum jump velocity.
| m/s | Somatropin | Control Arm |
|---|---|---|
| Baseline | 0.7 ± 0.22 | 0.6 ± 0.16 |
| Change at Month 6 | 0.2 ± 0.29 | 0.0 ± 0.18 |
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: five repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over the chest (time to perform the tasks, maximal PJP, maximal velocity and maximal PJF). Vmax is defined as the maximum jump velocity.
No measurements were reported for this outcome.
Chair rising test is performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: 5 repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over chest (time to perform tasks, maximal PJP, maximal velocity and maximal PJF). Time to perform task includes: Average (avg) rise time which is avg time to perform 1 rise, avg time per test is the avg time to perform 1 test (rise and sitting down) and total time to perform 5 tests.
| seconds | Somatropin | Control Arm |
|---|---|---|
| Baseline (Average rise time) | 1.2 ± 0.90 | 0.7 ± 0.31 |
| Change at Month 6 (Average rise time) | -0.5 ± 1.15 | 0.1 ± 0.27 |
| Baseline (Average time per test) | 2.0 ± 0.70 | 2.3 ± 0.60 |
| Change at Month 6 (Average time per test) | -0.2 ± 0.54 | -0.1 ± 0.87 |
| Baseline (Total time to perform 5 tests) | 9.6 ± 3.91 | 10.8 ± 2.24 |
| Change at Month 6 (Total time to perform 5 tests) | 0.1 ± 3.04 | 2.0 ± 8.48 |
Chair rising test is performance test (total power output) to measure neuromuscular function of complex movement in standing up. Test allows diagnostics of movement deficits using Leonardo jump plate. Five stand up test: 5 repetitions of rising from a chair on jump plate as quickly as possible with arms crossed over chest (time to perform tasks, maximal PJP, maximal velocity and maximal PJF). Time to perform task includes: Average (avg) rise time which is avg time to perform 1 rise, avg time per test is the avg time to perform 1 test (rise and sitting down) and total time to perform 5 tests.
No measurements were reported for this outcome.
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising). PJP is defined as the peak of the calculated power (force multiplied by velocity).
No measurements were reported for this outcome.
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising). PJF is the maximum force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms as high as possible with the head and chest.
No measurements were reported for this outcome.
The Chair rising test is a performance test (total power output) to measure neuromuscular function of complex movement to stand up. Test allows diagnostics of movement deficits using Leonardo jump plate. One stand up test: rising from a chair on the jump plate as quickly as possible with arms crossed over the chest (analysis of time, PJP, PJF and time of fastest rising).
No measurements were reported for this outcome.
MIGF was assessed using standard adjustable Jamar dynamometer. MIGF (in Newtons) was calculated by multiplying the dynamometer reading (in kilograms) by a factor of 9.81. The SDS indicates how similar the participant was to the reference population.
| kg | Somatropin | Control Arm |
|---|---|---|
| Change From Baseline in Maximal Isometric Grip Force-Standard Deviation Score (MIGF-SDS) at Month 6 | 1.28 ± 1.69 | 1.13 ± 1.64 |
MIGF was assessed using standard adjustable Jamar dynamometer. MIGF (in Newtons) was calculated by multiplying the dynamometer reading (in kilograms) by a factor of 9.81. The SDS indicates how similar the participant was to the reference population.
No measurements were reported for this outcome.
Bone Mineral Density (BMD) was measured by pqCT. The Z-score measures the distance of the measured BMD value from the appropriate normal age matched population mean value in units of standard deviation of this population. More negative scores indicate less BMD compared to age matched population and more positive scores indicate higher BMD compared to age matched population.
No measurements were reported for this outcome.
Bone structure was measured by pqCT.Parameters included:total area,cortical area,marrow area,cortical thickness,cortical density of the radius,bone strength,cross-sectional muscle and fat area,total bone density,bone mineral count,trabecular BMD,bone cross-sectional area.Baseline and post-baseline SDS values transformed to age and sex specific z-score(\[Ln(test result/M)\]/S);Ln=natural logarithm;M=age-/height- and sex-specific mean value;S=age-/height- and sex-specific coefficient of variation).Positive values are above the average for participant's age and sex;negative values are below.
No measurements were reported for this outcome.
Bone stability was measured by pqCT. Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- (or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Thigh measurements were taken as a mean of 3 consecutive measurements at upper thigh about an inch down from the crotch line.
No measurements were reported for this outcome.
Calf measurements were taken as a mean of 3 consecutive measurements at largest part of calf muscle, usually about 4 inches down from below the knee.
No measurements were reported for this outcome.
Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer.
| cm | Somatropin | Control Arm |
|---|---|---|
| Mean Height at Month 6 | 112.8 ± 5.13 | 115.0 ± 7.93 |
Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer.
No measurements were reported for this outcome.
Growth velocity measures the annual rate of increase in height.
| cm/year | Somatropin | Control Arm |
|---|---|---|
| Mean Growth Velocity at Month 6 | 8.2 ± 1.93 | 4.6 ± 1.44 |
Growth velocity measures the annual rate of increase in height.
No measurements were reported for this outcome.
Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population.
| cm | Somatropin | Control Arm |
|---|---|---|
| Mean Height-Standard Deviation Score (SDS) at Month 6 | -3.1 ± 0.86 | -3.7 ± 0.77 |
Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population.
No measurements were reported for this outcome.
Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population.
| cm/year | Somatropin | Control Arm |
|---|---|---|
| Mean Growth Velocity-Standard Deviation Score (SDS) at Month 6 | 3.4 ± 2.62 | -1.1 ± 1.43 |
No measurements were reported for this outcome.
Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population.
| cm | Somatropin | Control Arm |
|---|---|---|
| Change From Baseline in Height-Standard Deviation Score (SDS) at Month 6 | 0.33 ± 0.21 | -0.22 ± 0.25 |
Standing height was taken as a mean of 3 consecutive measurements using a wall mounted stadiometer. The SDS indicates how similar the participant was to the reference population.
No measurements were reported for this outcome.
Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population.
| cm/year | Somatropin | Control Arm |
|---|---|---|
| Change From Baseline in Growth Velocity-Standard Deviation Score (SDS) at Month 6 | 3.89 ± 1.02 | -0.77 ± 1.40 |
Growth velocity measures the annual rate of increase in height. The SDS indicates how similar the participant is to the reference population.
No measurements were reported for this outcome.
PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during two-leg jump. The SDS indicates how similar the participant was to the reference population.
| Newtons | Somatropin | Control Arm |
|---|---|---|
| Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6 | -0.83 ± 1.27 | -0.85 ± 0.73 |
Vmax was measured by Leonardo Jumping Platform during two-leg jump.
| Meter/second (m/s) | Somatropin | Control Arm |
|---|---|---|
| Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6 | 0.01 ± 0.08 | 0.12 ± 0.09 |
Vmax was measured by Leonardo Jumping Platform during two-leg jump.
| m/s | Somatropin | Control Arm |
|---|---|---|
| Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Per Protocol (PP) Population at Month 6 | 0.01 ± 0.05 | 0.25 ± 0.06 |
Sitting height was measured using a stadiometer with a specialized chair. The SDS indicates how similar the participant was to the reference population.
No measurements were reported for this outcome.
The BMI was used to measure body fat based on height and weight. It was calculated by body weight (kg) divided by the height (m) squared. The SDS indicates how similar the participant was to the reference population.
No measurements were reported for this outcome.
The maximum head circumference (usually horizontal just above the eyebrow ridges), was measured from just above the glabella area to the area near the top of the occipital bone (opisthocranion).
No measurements were reported for this outcome.
The maximum head circumference (usually horizontal just above the eyebrow ridges), was measured from just above the glabella area to the area near the top of the occipital bone (opisthocranion). The SDS indicates how similar the participant was to the reference population.
No measurements were reported for this outcome.
Triceps, supra-iliac and subscapular skinfolds were measured on the right side of the body to the nearest 0.1 mm with a Holtain skinfold caliper. The measurement was performed at the left side of the participant. Triceps skinfold thickness was measured halfway down the left upper arm, while the arm was hanging relaxed at the participant's side. Suprascapular skinfold was measured laterally just below the angle of the left scapula. Suprailiac skinfold was measured just above the iliac crest in the middle-axillary line. SDS indicates how similar the participant was to the reference population.
| Millimeter (mm) | Somatropin | Control Arm |
|---|---|---|
| Change at Month 6 (Triceps SDS) | -0.41 ± 0.16 | -0.06 ± 0.18 |
| Change at Month 6 (Subscapular SDS) | -0.30 ± 0.10 | -0.16 ± 0.13 |
| Change at Month 6 (Suprailiac SDS) | -0.60 ± 0.07 | -0.33 ± 0.12 |
Triceps, supra-iliac and subscapular skinfolds were measured on the right side of the body to the nearest 0.1 mm with a Holtain skinfold caliper. The measurement was performed at the left side of the participant. Triceps skinfold thickness was measured halfway down the left upper arm, while the arm was hanging relaxed at the participant's side. Suprascapular skinfold was measured laterally just below the angle of the left scapula. Suprailiac skinfold was measured just above the iliac crest in the middle-axillary line. SDS indicates how similar the participant was to the reference population.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Somatropin | — | 0/12 (0%) | 10/12 (83.3%) |
| Control Arm | — | 0/11 (0%) | 7/11 (63.6%) |
| Event | Somatropin | Control Arm |
|---|---|---|
| HeadacheNervous system disorders | 2/12 | 2/11 |
| Respiratory tract infectionInfections and infestations | 2/12 | 0/11 |
| ConjunctivitisEye disorders | 0/12 | 1/11 |
| ConstipationGastrointestinal disorders | 0/12 | 1/11 |
| Acute tonsillitisInfections and infestations | 0/12 | 1/11 |
| BronchitisInfections and infestations | 0/12 | 1/11 |
| GastroenteritisInfections and infestations | 0/12 | 1/11 |
| Otitis mediaInfections and infestations | 1/12 | 1/11 |
| RhinitisInfections and infestations | 0/12 | 1/11 |
| TonsillitisInfections and infestations | 0/12 | 1/11 |
| Age Continuous(Years) | Somatropin | Control Arm | Total |
|---|---|---|---|
| Mean | 6.6 ± 1.0 | 7.6 ± 1.4 | 7.1 ± 1.3 |
| Sex: Female, Male(Participants) | Somatropin | Control Arm | Total |
|---|---|---|---|
| Female | 3 | 8 | 11 |
| Male | 9 | 3 | 12 |
The record gives a start of Jul 2008, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone